Talk:Alendronic acid

Fastly reached??
In the Pharmocokinetics section, I'm not at all sure that the sentence "Soft tissues and bones are fastly reached by about 50%" means anything. Is "fastly" even a word? I may be bold and remove it soon. Mike Field 10:36, 1 February 2007 (UTC)

Newly reported side effects
The FDA site, MedlinePlus, has side-effect warnings not mentioned in this article. Not being a health professional, I hope that a competent editor will revise the article to include this info. 85.250.145.80 (talk) 11:52, 25 May 2008 (UTC)

Litigation section
I have removed the litigation section because I don't think it is appropriate for the article - at least as written. Details such as naming and shaming one individual for a tactless email is hardly acceptable material for this article. Not only does it violate WP:UNDUE and WP:BLP, but it certainly comes across as if the only reason it is the article is for the purpose of carrying out some individual's grudge against a company. It is a clear case of WP:COATRACK. Maybe there is a way to appropriately incorporate some of the litigation issues associated with alendronic acid, but as currently written the paragraph is entirely unacceptable. ChemNerd (talk) 14:52, 19 February 2013 (UTC)

What is the actual chemical
Is the actual chemical the neutral bisphosphonic acid (as file:Alendronic acid.svg in the infobox) or the fully deprotonated (tetra-anionic) form (as file:Alendronate-3D-balls.png in the infobox)? The lead sentence uses the acid and the sodium-salt forms as if they were synonyms, but that doesn't make chemical sense, despite possibly being pharmacologically equivalent. I have no problem with the inclusion of both because it's a "drug" not "chemical" article, but it's confusing that things aren't self-consistent. DMacks (talk) 07:14, 2 February 2016 (UTC)

Broken link
Link 8 FDA Patient Safety News, March 2008 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=73#3 give "Page not found" — Preceding unsigned comment added by 82.2.126.9 (talk) 11:46, 9 April 2019 (UTC)

Oral vs intravenous
Under Medical uses, should we distinguish oral from intravenous administration (since the oral bioavailability is noted as v low) and the higher/intravenous doses are used for non-osteoporosis including bone cancer, and may have different side effects ? - Rod57 (talk) 10:26, 4 October 2021 (UTC)


 * I agree; I know someone who is on intravenous Alendronic acid to prevent osteoporosis being caused by other medication. This does not seem to be uncommon, and yet the lede of this article asserts "It is taken by mouth". Andy Mabbett ( Pigsonthewing ); Talk to Andy; Andy's edits 16:41, 29 October 2022 (UTC)
 * Are we actually still giving alendronic acid IV? I've only every seen it PO (at least in the UK).
 * To give a bit more detail, as far as I know, the bisphosphonates that we may give IV are pamidronate, ibandronate and zoledronate. But not alendronate. Dr. Vogel (talk) 11:59, 30 October 2022 (UTC)
 * Alendronic acid IV is not approved in the US or the UK. I nerdsniped two pharmacists in the MICU over this and we had a great time digging up info about it. Martindale's lists a few preparations but I had trouble finding any that were actively marketed/used/produced. IV alendronate is produced by Teijin Pharmaceuticals and approved for use in Japan at a dose of 900 mcg under the name Bonalon.  PAHO suggests that it is available at a dose of 4 mg in Barbados, but I couldn't find the manufacturer or trade name. Everywhere else in the world, IV pamidronate, zoledronate, and ibandronate are used as best I can tell. Keilana (talk) 15:17, 30 October 2022 (UTC)
 * Ok, so we got to more or less the same conclusion, that's excellent.
 * So, about the alendronic acid article then.. should we talk about it as a PO medication, but mention somewhere those 2 examples of countries that you found? Dr. Vogel (talk) 17:26, 30 October 2022 (UTC)
 * I accompanied the patient to whom I referred for their annual infusion, yesterday, at a major NHS hospital in England. On asking they were told they were being given "Alendronic acid". Andy Mabbett ( Pigsonthewing ); Talk to Andy; Andy's edits 16:05, 31 October 2022 (UTC)
 * I have now been shown the patient's appointment letter (for their next infusion, in October 2023!) and it refers to "Zolendronate". I see we have no entry for Zolendronate, although Zoledronate redirects to Zoledronic acid. Andy Mabbett ( Pigsonthewing ); Talk to Andy; Andy's edits 12:32, 8 November 2022 (UTC)
 * "Zolendronate" is not a thing. The drug is Zoledronate / zoledronic acid. And this is drug is indicated for IV infusion. Dr. Vogel (talk) 13:34, 8 November 2022 (UTC)
 * Nonetheless, that is the spelling used in the letter (I double checked before posting my last) and Google finds several hits, including on PubMed, on clinicaltrials.gov, and on nhs.uk, for that spelling. Andy Mabbett ( Pigsonthewing ); Talk to Andy; Andy's edits 14:11, 8 November 2022 (UTC)
 * Yeah I think we're so used to "alendronate" that sometimes we make up an intrusive N in zoledronate. You spend X many hours in hospital every day and you hear something again and again and again and in the end you don't even know whether the N should be there or not. There are lots of other examples like that. But I'm pretty sure this drug does not have an N. Dr. Vogel (talk) 14:31, 8 November 2022 (UTC)